Cashmaker's hot stocks and trading

comment on EBAY:

comment on EBAY:
Although ebay been down for a longtime due to its increased commition fee and lost some customer to other competitors and only 2 cents earning top on the expectation, at least from TA, it will rebounce. Article mention that GOOG is cheaper than EBAY, I think this is not true. People always predict things according to the recent historical data, when it is uptrend ,people are hype and pump, overbought the already-up-stock. The other way around, when price down, people always dump and criticize the company, think about it, why those critique all come out after fact, why they don't bring it out when the price was skyrocket. This is called overreaction. So when the price is too low due to oversold, it is time to buy.
 
WTSLA My short term target $8, longterm $13

My short term target $8, longterm $13

Wet Seal, the women's apparel retailer, looks to be heading down the road to recovery. The company's fiscal-first-quarter (ended April 30th) share loss narrowed to $0.23, from the $0.52 deficit registered in the year-ago period. Wet Seal reduced operating expenses considerably in the period by closing more than 150 of its non-profitable stores. Meanwhile, same-store sales improved an impressive 30% in the April period.


From WSJ:
The Wet Seal, Inc. Announces May Comparable Store Sales Up 56.9%

Business Wire
(c) 2005 Business Wire. All Rights Reserved.

FOOTHILL RANCH, Calif. - (BUSINESS WIRE) - June 2, 2005 - Specialty retailer The Wet Seal, Inc. (Nasdaq:WTSLA) today reported net sales for the four-week period ended May 28, 2005 of $40.0 million, compared with net sales of $33.0 million for the same period last year, an increase of 21.1 percent. Comparable store sales from continuing operations increased 56.9 percent for the four-week period ended May 28, 2005, compared with a decline of 7.8 percent for the same period a year ago.

Mr. Joel Waller, chief executive officer of The Wet Seal, Inc. commented: "May represents the fifth consecutive month of comparable store sales growth since the implementation of our new merchandise strategy in January for the Wet Seal business. Our results continue to validate our strategy and we are pleased with the sales performance of both Wet Seal and Arden B."

During the four-week period ended May 28, 2005, the Company opened one Wet Seal store.

Headquartered in Foothill Ranch, California, The Wet Seal, Inc. is a leading specialty retailer of fashionable and contemporary apparel and accessory items. The company currently operates a total of 399 stores in 46 states, the District of Columbia and Puerto Rico, including 308 Wet Seal stores and 91 Arden B. stores. The company's products can also be purchased online at www.wetseal.com or www.ardenb.com . For more company information, visit www.wetsealinc.com .
 
In SCHN here, bullish chart and bottom confirm. Compare to is competitors, like NUE,

In SCHN here, bullish chart and bottom confirm. Compare to is competitors, like NUE, OS, SCHN is undervalued. SCHN's FA is decent, plus Steel industry will do good shorttermly this year. Short-term target $30, long term target $50
 
Comment on SCHN.

Comment on SCHN.
Although NUE announce the lower end of its earning prediction for 2Q, SCHN is not a steel producer and it should not be compared directly with NUE.

Second, If you look at their June 5 report, you can predict the Schnitzer's sales are about double the reported values, moreover if you include their share of the joint venture which accounts for a significant share of profits to SCHN.

http://library.corporate-ir.net/library/87/870/87090/items/155021/060905presentation.pdf

Base on SCHN's potential future scrap demand, and SCHN's auto parts business, the 3Q for SCHN should be good. I analyse and predict the earning correctly consecutively for GMTN 10Q, LAZ 1Q, NGPS 2Q, KOMG 1Q this year.
 
News: JPM Reports 15.6% LAZ Stake

News: JPM Reports 15.6% LAZ Stake
(c) 2005 Dow Jones & Company, Inc.

WASHINGTON (Dow Jones)--JPMorgan Chase & Co. (JPM) reported a 15.6% Class A stake in Lazard Ltd. (LAZ), according to a Schedule 13G filed Monday with the Securities and Exchange Commission.

JPMorgan, one of the underwriters for Lazard's initial public offering in May, beneficially owns 5.86 million Lazard Class A common shares, the filing said.

JPMorgan reported its stake on a form designated for passive investors, or those not seeking to change or influence a company's operation.

Shares of Lazard closed Monday at $23.67 each.

LAZ definately a Strong buy, Fidelity require 15% stake of LAZ three weeks ago and give the target $27. Now JPM bought another 15.6% stake. Take a look at how many merge & acquicition cases these days (almost every day), you can figure out the M&A business for LAZ.
 
M&A is booming, we see the M&A happen everyday. LAZARD is the number one in this fiel

M&A is booming, we see the M&A happen everyday. LAZARD is the number one in this field, its business is growing. Here is today's news from WSJ:

June 24th 2005, Callaway Golf Mulls Strategy; Investor Group Makes an Offer

By Stephanie Kang

"the Carlsbad, California, company said that it has received unsolicited "indications of interest" and was weighing strategic options with the help of investment bankers Lazard Ltd. "
 
LAZ volume alert: in the last 30 min, volume increase suddently to 75K. You can see t

LAZ volume alert: in the last 30 min, volume increase suddently to 75K. You can see this by checking minute chart with volume. Just some observe.
 
HLTH good entry here. Health care sector. Uptrend Momentum with solid financial backg

HLTH good entry here. Health care sector. Uptrend Momentum with solid financial background.
 
LAZARD Research report:

LAZARD Research report:

(http://biz.yahoo.com/prnews/050705/nytu049.html?.v=15)
PricewaterhouseCoopers Forecast: M&A Market Heats Up

(http://www.forbes.com/facesinthenews/2005/07/05/0705autofacescan11.html?partner=yahootix&referrer=)

Wasserstein's Lazard (nyse: LAZ - news - people ) came in 10th place In M&A Business.

(http://www.ajc.com/wednesday/content/epaper/editions/wednesday/business_24bca6d69074f00a0007.html)

Mergers up 39% from last year, gobal merger-and-acquisition volume rocketed to $1.4 trillion in the first half of 2005, an increase of 39 percent from the same period last year. Finance was the most active industry, accounting for $238 billion of the deal volume.

(http://home.businesswire.com/portal...d=news_view&newsId=20050701005166&newsLang=en)

The good news for U.S. dealmakers is that deal value has skyrocketed, indicating a willingness among buyers in the U.S. and U.S. cross-border market to open the purse strings for acquisitions. Total disclosed dollar volume for the second quarter jumped to U.S.$275 billion, the highest quarterly deal value since the fourth quarter of 2000 and an improvement over the U.S.$243 billion total for the first quarter. Increasing deal value can be attributed to ongoing strength of the mega-deal market (defined by FactSet Mergerstat as deals with values of more than U.S.$1 billion). The second quarter posted 55 deals in this category, up from 34 last quarter.


(http://austin.bizjournals.com/austin/stories/2005/07/04/daily6.html)
M&A pace to continue for rest of '05. Without a doubt, U.S. corporations plan to continue their rapid pace of acquisitions"

LAZ 3 month target $26.5, Over $30 by the end of 2005.
Look at how hot the M&A business is this year and this trend will go on in the next few years, just like what we experienced in 1980s'. LAZARD is the top 10 M&A investment bank with M&A business in US, EURO, JAPAN, and more.
 
Regeneron testing therapy for blindness cause July 6th 2005

Regeneron testing therapy for blindness cause July 6th 2005
Times Union
THREE STAR
E1
Copyright (c) 2005 Bell & Howell Information and Learning Company. All rights reserved.

EAST GREENBUSH - Regeneron Pharmaceuticals Inc. has begun testing its VEGF Trap, which it hopes will prevent blindness caused by the "wet" form of age-related macular degeneration, or ARMD.

The disease is a major cause of vision impairment and blindness in adults over age 55.

Regeneron's Phase 1 trial is a dose-escalating study designed to assess the safety and tolerability of VEGF (Vascular Endothelial Growth Factor) Trap in patients. It is one of several clinical studies that must be completed before the drug can be submitted for U.S. Food and Drug Administration approval.

Regeneron, based in Tarrytown, has a research and manufacturing site in East Greenbush.

- Alan Wechsler

TMNN000020050706e1760008k




Hoover's Company Profiles, Copyright(c), 2005, Hoover's, Inc., Austin, Tx

Regeneron isn't the Pentagon, but the firm is fighting some serious enemies. Regeneron Pharmaceuticals develops protein-based drugs used to treat a variety of diseases and conditions, including cancer, asthma, and cardiovascular conditions. The biotechnology firm focuses on discovering and developing neurotrophic factors, proteins required for neurons to survive. Regeneron is developing several drug candidates based on its neurotrophic research. Its lead candidate, AXOKINE, targets obesity but its results in clinical trials have been disappointing so far. The company also is collaborating with Aventis Pharmaceuticals on VEGF Trap as a possible treatment for tumors.
 
ADBE Undervalued. Target: $36 UPDATE: Slumping Adobe Shares Could Be Set For Turnarou

ADBE Undervalued. Target: $36 UPDATE: Slumping Adobe Shares Could Be Set For Turnaround

518 words
7 July 2005
01:43 pm
Dow Jones News Service
English
(c) 2005 Dow Jones & Company, Inc.

(Updates stock price and adds Department of Justice declining to comment in last paragraph.)


NEW YORK (Dow Jones)--Shares in Adobe Systems Inc. (ADBE) have been in a funk, slumping nearly 20% since the beginning of June, amid concerns about its acquisition of Macromedia Inc. (MACR). But the shares could be in store for a turnaround.

Analysts said the concerns, including over a possible delay of the deal and potential competition obstacles, are overblown and the stock weakness makes for a good time to buy.

Karen Haus, an analyst with WR Hambrecht, recommended buying Adobe shares at current prices, reiterating her $36 price target.

Haus' valuation assumes a premium over other software vendors, but that's "justified in our opinion due to the company's excellent growth prospects and strong competitive positioning," she said in a note. WR Hambrecht didn't report any notable conflicts of interest on its Web site.

Prudential and UBS also issued similar supportive statements about Adobe. Smith Barney, however, recommended investors stay on the sidelines until concerns over a possible delay of the Macromedia deal are cleared up.

Prudential owns shares in Adobe. UBS has a banking relationship with the company. Smith Barney didn't disclose any significant conflicts of interest.

The positive comments helped lift the shares Thursday. They were recently trading at $27.50, up 58 cents, or 2.2%. Still, in early June, the shares were comfortably above $33. Macromedia shares recently were up $1, or 2.8%, at $36.89.

Adobe, which created the ubiquitous portable document format and makes the popular Photoshop design software, gets overwhelmingly high marks from the investment community. Seventeen out of 23 analysts that cover the company rate the stock at a buy or strong buy, according to Thomson Financial.

Its $3.4 billion pairing with Macromedia - the maker of Flash, which facilitates multimedia Internet pages - was considered a great match. The deal will swap 0.69 Adobe shares for every Macromedia share. Following the deal, Adobe plans to buy back $1 billion in stock in order to limit the dilution.

Still, hiccups in the all-stock deal, which have included a refiling of the deal notification, a shareholder lawsuit and a restatement of Macromedia's past earnings, have combined with conservative earnings guidance and a security flaw in an older, limited-release version of Acrobat reader to weigh on investor sentiment.

But analysts say there are a number of upcoming events that could provide a catalyst to a rise in the shares. On Friday, the Department of Justice is expected to respond to the Macromedia deal. On July 20, Macromedia will announce its fiscal first-quarter earnings, and perhaps most importantly, Adobe will provide a midquarter update on Aug. 1.

Adobe reiterated that the Macromedia deal will close in the fall, but declined to comment on its stock move. A spokeswoman for the Department of Justice declined to comment.


Document DJ00000020050707e177000lm
 
Valueline Comment on ADBE Timeliness 1,target $35.

Valueline Comment on ADBE Timeliness 1,target $35.
Adobe Systems has agreed to acquire Macromedia in an all-stock transaction, valued at about $3.4 billion. Adobe will pay .69 of a share for each Macromedia share. The deal, which has been approved by the board of directors of both companies, is still subject to regulatory approval. We expect the transaction to close in the fall. Although the acquisition will probably be slightly accretive to earnings, we are not including these contributions in our results until it is finalized.

The purchase of Macromedia will likely help Adobe expand its product offerings. Adobe's Acrobat program allows Internet users to create simple documents. Most of the customers using this program will likely be interested in purchasing Macromedia's Internet design products. Macromedia has also been making advances in the mobile device marketplace. As such, the combination of the two businesses, which spend a considerable amount on research and development, should create significant opportunities. This should help Adobe to compete against large technology companies planning to enter the Internet and graphics marketplace.

Adobe's results should get a boost from the recent upgrade of its creative suite. In addition to previously released design programs, the enhancements includes new software upgrades. The creative suite should help users consolidate their software purchases, as well as promote Adobe's programs.

The earnings outlook is improving. The company reported strong top- and bottom-line results in the first quarter of 2005 (year ends November 30th). We expect this strength to continue going forward. We are increasing our earnings estimate for 2005 slightly, and are introducing an earnings estimate of $1.25 for 2006. Our figures have been adjusted for a recent 2-for-1 stock split.

These shares are ranked 1 (Highest) for Timeliness. The earnings outlook is bright. In addition, our current projections indicate that these shares offer worthwhile appreciation potential for the next 3 to 5 years. The recent decline in Adobe's stock price probably reflects investors' concern about the upcoming acquisition.

May 27, 2005
 
Two new stocks in my Tech portfolio: ADBE,CSCO. ADBE target $36, CSCO: $25

Two new stocks in my Tech portfolio: ADBE,CSCO. ADBE target $36, CSCO: $25

REGN, HLTH, SCHN, OS, LAZ,RHAT My recent call, all are strong financial background and with great uptrend chart.
 
Big news for LAZ. Another 10.71% stake by Jennison Associates. Reports 10.71% Stake I

Big news for LAZ. Another 10.71% stake by Jennison Associates. Reports 10.71% Stake In Lazard

131 words
8 July 2005
03:19 pm
Dow Jones International News
English
(c) 2005 Dow Jones & Company, Inc.

WASHINGTON (Dow Jones)--Jennison Associates LLC reported a 10.71% stake in Lazard Ltd. (LAZ), according to a Schedule 13G filed Friday with the Securities and Exchange Commission.

Jennison Associates, an investment adviser to several investment companies, insurance accounts and institutional clients, beneficially owns about 4 million Lazard common shares, the filing said.

Prudential Financial Inc. (PRU) indirectly owns 100% of the equity interests of Jennison, so Prudential may also be deemed to beneficially own these Lazard's shares, the filing said.

Jennison Associates reported its stake on a form designated for passive investors, those not seeking to change or influence a company's operations.

-By Denise Jia, Dow Jones Newswires; 202-862-1359; [email protected] [ 08-07-05 2022GMT ]

Document DJI0000020050708e178001hu

So Far, JP Morgan 15%, BOA 15% Prudential 10.71%. These major holder are Banks and Insurance companies, they have their good reason to require so much stake into LAZARD, they know exactly what LAZ's future is. LAZ still under IPO, go buy.

http://www.sec.gov/Archives/edgar/data/1311370/000005341705000077/0000053417-05-000077-index.htm
 
RHAT $16 target by most Analyst. Good Support at $14 level. Will see more appreciatio

RHAT $16 target by most Analyst. Good Support at $14 level. Will see more appreciation follow analyst recommend.
 
SCHN $27, just $1 from my target, will hold till $28 short term. Call from $23. LAZ w

SCHN $27, just $1 from my target, will hold till $28 short term. Call from $23. LAZ will see its IPO price back in several weeks.
 
Holding ADBE to $30. REGN target $15 and LAZ target $26.5. SOLD SCHN above $27 today.

Holding ADBE to $30. REGN target $15 and LAZ target $26.5. SOLD SCHN above $27 today. Holding OS.
 
THis is why LAZ worth at least $26.5

THis is why LAZ worth at least $26.5
Take a look at this link and you will know why LAZ target is $26.5. However my target is not just based on these analyst opinion, but from FA my model.
http://finance.yahoo.com/q/ao?s=LAZ

Article from WJS:
U.S. deal makers still lead the M&A world

July 14th 2005
AFX Asia
(c) 2005, AFX Asia. All rights reserved.

NEW YORK (XFN-ASIA) - When Chinese oil company CNOOC Ltd. Stunned the markets by making a $18.5 billion bid for Unocal Corp. last month, it didn't lean on China's burgeoning banking industry.

Nor did the company go to any Asian-based firm to advise them on the deal. Instead, like many foreign companies, it sought American-made advice from Goldman Sachs Group Inc. , J.P. Morgan Chase and legal advice from Davis Polk & Wardwell.

As CNOOC's choice suggests, Chinese mergers and acquisitions may be grabbing headlines, but U.S. investment banks continue to be grabbing the fees for advising on deals.

"They have a vast wealth of experience, detailed home country knowledge and are very adroit at hiring people from every country," said James Owers, a Harvard University associate and finance professor at Georgia State University. "When you overlay that with the traditional experience you have competitive advantage."

Indeed, though M&A is up in countries around the world, including Japan, the United Kingdom, Italy, Germany, Spain and Russia, the U.S. market remains the hottest with $593 billion in deals through the first half of the year, up 35%, according to Dealogic.

China's M&A market is actually having a slower year through the first half, down 15% to $23 billion. That puts the People's Republic 11th globally behind countries like Canada, Australia and the Netherlands.

U.S. leaders

Through the first half of 2005, four of the top five global advisers were U.S.-based firms: Morgan Stanley , Goldman Sachs, Merrill Lynch & Co. and J. P. Morgan ranked one through four. Swiss bank UBS placed fifth.

Owers cautions that U.S. banks and sellers such as Unocal may learn a lesson from the late 1980s and early 1990s. At that time, foreign buyers, including many from Japan, bought U.S. assets. The fear about foreign ownership incited nationalism and protectionism, Owers said. But, in the end, the sellers and bankers were the ones who profited.

"If someone offers you more than market price, give them the keys and let them drive it away," Owers said.

Shrinking competition

It was only a few years ago when firms such as Lazard Ltd., Cazenove, and Schroeders were considered top competitors emerging from Europe.

But Lazard booted its European management for U.S. banker Bruce Wasserstein and went public on the New York Stock Exchange. J.P. Morgan bought a 50% stake in Cazenove in 2004 and Schroeders was acquired by Citigroup for $2.2 billion in 2000.

In their place, banks such as HSBC Holdings under John Studzinski, Deutsche Bank , Dresdner Kleinwort Wasserstein and Nomura remain second-tier players with bigger ambitions.

Even in Europe

U.S. banks remain the heavyweights in Europe taking advising roles in the two biggest deals of the year. When Bayerische Hypo Vereinsbank agreed to be acquired by UniCredito Italiano in June for $18.6 billion, J.P. Morgan, Citigroup, and Deutsche Bank advised the target. Merrill Lynch and Goldman advised the buyer.

Likewise when Pernod Richard and Fortune Brands agreed to buy Allied Domecq in April for $17.7 billion, Goldman advised Allied, three U.S. banks advised the buyer with Deutsche Bank, CSFB and BNP Paribas.

That U.S. firms are leading the deals isn't new and isn't likely to change.

"They are aggressive in their strategy," Owers said. "If you're good at something and have a good strategy...you will be dominant."

This story was supplied by MarketWatch. For further information see www. marketwatch.com.

MMMM
 
Regeneron Pharmaceuticals Attend July 22th Obesity Drug Development Summit http://www

Regeneron Pharmaceuticals Attend July 22th Obesity Drug Development Summit http://www.cbinet.com/show_conference.cfm?confCode=HB549&field=daytwo

In Vivo Target Discovery and Validation by High Throughput Genome Engineering
A high throughput genome engineering technology platform has been developed to determined the in vivoexpression pattern of many novel obesity and diabetes-related genes at high resolution, validate and invalidate putative targets as well as dissected important metabolic pathways. This method also provides important insights into mechanisms of novel compounds currently in development for the treatment of obesity and diabetes.

Overview of technology
Validation and invalidation of diabesity targets using KO models
SHIP2 lipid phosphatase as target for treatment of obesity
Mark W. Sleeman, Ph.D., Director of Neural and Endocrine Biology,Regeneron Pharmaceuticals Inc.

Watch REGN these days, getting hotter and hotter. Valueline raise its timeliness on June based on REGN's much-better-than-before financial statement and its new drugs research with its target $15. Three years target from Valueline is $25.
 
SCH on fire. Strong Earning and positive guidance

SCH on fire. Strong Earning and positive guidance
 
Top